Navigation Links
Advances in Delivery to the Central Nervous System
Date:9/19/2012

NEW YORK, Sept. 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Advances in Delivery to the Central Nervous System

http://www.reportlinker.com/p0968584/Advances-in-Delivery-to-the-Central-Nervous-System.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

 

The blood-brain barrier (BBB) and the blood cerebrospinal fluid barrier (BCSFB) exist to protect the brain, stringently regulating substances into and out of the brain. This report examines the ways in which these natural barriers may be overcome or circumvented to ensure that drugs can reach their intended target in the brain.Identify the five main strategies for maximizing the delivery of drugs to the brain.Understand the scientific basis of the most promising and recent technology advances.Identify the companies that are at the cutting edge of each type of delivery technology.Gain insight from quotes and opinions from leaders in the field of CNS drug delivery.Assess which types of delivery technology are best suited to which types of drug and therapy area.Increasingly, drug delivery specialists are harnessing endogenous BBB mechanisms such as receptormediated delivery pathways with nano-enabled platform technologies to improve the uptake and targeted delivery of substances into the brain.Improvements in intranasal delivery devices and advances in formulation technologies have enabled researchers to deliver a wide range of substances in therapeutic doses into the olfactory regions. Medical device companies Kurve Technology, Impel NeuroPharma, and OptiNose have all developed devices that are compatible with intranasal delivery.Chemical modification (e.g. lipidation and cationization) can be used to improve passive delivery across the blood-brain barrier but is rarely used in isolation. Permeability enhancers can be used to transiently disrupt the BBB to allow the passage of drugs into the CNS, but they have yet to be fully validated in the clinic.Which delivery technologies can be considered for a drug that needs to achieve high CNS penetration?What types of chemical modification have been applied and how successful have these been?What role can nanotechnology play in drug delivery?How well validated are the delivery technologies and which have data from human trials?Are there in indications in which the problems of blood-brain barrier penetration can be justifiably circumvented by direct injection or implantation?

 

 

 

About the author

•Disclaimer

EXECUTIVE SUMMARY

•Strategies for drug delivery to the brain

Introduction

•Key factors in the development of improved methods of drug delivery to the central nevous system

Strategies for drug delivery to the brain

•Delivery of drugs across the BBB

•Direct injection and implantation

- Conclusions on direct injection and implantation

•Chemical modifications

- Lipidation

- Cationization

- Prodrugs

- CNS "locked" prodrugs

- Carrier-mediated prodrugs

- Receptor-mediated prodrugs

- Conclusions on chemical modifications

•Permeability enhancers

- Efflux transporter inhibitors

- Conclusions on permeability enhancers

•Nano-enabled delivery technologies

- Liposomes

- Case study: G-Technology (to-BBB Technologies BV)

- Bolaamphiphiles

- Case study: V-Smart technology (Lauren Sciences)

- Nanoparticles

•Receptor-mediated delivery technologies

- Case study: EPiC technology (Angiochem)

- Other receptor-mediated delivery technologies

•Conclusions on nano-enabled and receptor-mediated delivery technologies

•Intranasal delivery

- Mechanism of intranasal delivery

- Intranasal delivery of biopharmaceuticals

- Intranasal formulations

- Intranasal devices

- Case study: POD device (Impel NeuroPharma)

- Intranasal conclusions

•Overall conclusions

Appendix

•Scope

•Methodology

- Research methodology

- Acknowledgements

•Abbreviations

•Bibliography/references

 

TABLES

 

•Table: Products approved for intrathecal delivery

•Table: Inhibitors of blood-brain barrier efflux transporters

•Table: Receptor-mediated targeting ligands

 

FIGURES

 

•Figure: Enhancing lipophilicity may increase CNS delivery

•Figure: Schematic of the prodrug approach for CNS delivery

•Figure: Chemical structures of both exogenous and endogenous LAT substrates

•Figure: Schematic of G-Technology

•Figure: Schematic of nose-to-brain pathways for drugs

•Figure: Intranasal delivery devices

 

 

 

Companies Mentioned

Alkermes plc, Arriva plc, Bank of Taiwan, GE Healthcare, Geron Corporation, GlaxoSmithKline Plc, Hutchison 3G UK Limited, Informa plc, Invacare Corporation, Kewill plc, PepsiCo, Inc., Publicis Groupe SA, Sanofi, WPP Group plc

 

 

 

To order this report:

Drug_Delivery_Technology Industry: Advances in Delivery to the Central Nervous System

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accelrys ELN Advances Innovation Lifecycle Management with Enhanced Biology Capabilities from Screening to Preclinical Development
2. Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits
3. Neurostimulation Devices Market to 2018 - Technological Advances and Robust Pipeline with Multi-Indication Potential and Non-Invasive Therapies to Drive Growth
4. URAC sets standards for community pharmacy, advances dialogue about pharmacists as medication experts
5. Ampio Advances NCE001 Cancer Drug into Preclinical Development Following Successful Recent Financing and the Granting of Patents in USA, Canada, Europe and China
6. Medical Imaging Information Systems Market to 2017 - Replacement of Legacy Systems and Advances in Software Present Growth Opportunities
7. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
8. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
9. Top 10 Drug Delivery Technologies (2010 - 2015)
10. Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance
11. Injectable Drug Delivery to 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):